Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Celgene Corporation (NASDAQ: CELG), 3SBio Inc. (NASDAQ: SSRX), AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), LM Ericsson Telephone Company (NASDAQ: ERIC) and Amylin Pharmaceuticals (NASDAQ: AMLN).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579

Here are highlights from Monday’s Analyst Blog:

Celgene Has a Strong Quarter

Celgene Corporation (NASDAQ: CELG) reported strong 4th quarter financials on January 29, 2009 which were in line with our expectations. We maintain a Buy rating on its shares.

Total revenue came in at $628.3 million, up 51.5% from $414.6 million in the 4th quarter of 2007. 4Q08 revenue was in line with our estimate of $627.1 million. Total revenue comprised of product sales, royalty and collaboration revenue. Net product sales in 4Q08 were $596.1 million, up 57% from $380.5 million in 4Q08. Net product sales were $6.3 million short of our expectations. Royalty revenue in 4Q08 was $27.1 million, $4.6 million over our estimate of $22.5 million. Collaboration revenue was $5.0 million, $2.8 million over our estimate of $2.2 million.

3SBio a Top Chinese Biotech

3SBio Inc. (NASDAQ: SSRX) is a China-based biotech company focused on developing and marketing therapeutics for nephrology, oncology and cancer supportive care. The company's flagship product, EPIAO, is the number 1 brand in the erythropoietin (EPO) market.

Second lead product TPIAO has gained rapid physician acceptance for thrombocytopenia and is making a meaningful contribution to the company's top line growth. Recent deals with US-based AMAG Pharmaceuticals Inc. (NASDAQ: AMAG) will boost its expansion into the IV Iron market, which will sustain long-term growth.

Ericsson Called Fairly Priced

Headquartered in Stockholm, Sweden, LM Ericsson Telephone Company (NASDAQ: ERIC) is a multinational company engaged in manufacturing and selling wireless infrastructure equipment for the telecom sector. It is a total network solutions provider, serving wireless and wireline operators, enterprises, and consumers.

Ericsson reported higher revenues but lower-than-expected earnings for 4Q08. The company experienced operator consolidation and delays in mobile telecom roll-outs across Western & Eastern Europe, Australia and Japan, which caused its product mix to be more-heavily weighted towards lower-margined products and services. This, along with costs of integration, reduced the company's overall margins and earnings significantly during the 4th quarter.

Amylin Caught In The Middle

This morning, Eastbourne Capital Management LLC announced its intentions to nominate a minority slate of five individuals for elections to the 12-member Board of Directors at Amylin Pharmaceuticals (NASDAQ: AMLN).

Eastbourne also stated in a letter to the current Amylin Board indicating its enthusiasm for the pipeline and products, but that it has lost confidence in the ability of the Board and management team to execute an operational strategy that is in the best interest of shareholders. As of the last filing, Eastbourne owns approximately 12.5% of Amylin's outstanding common stock.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=2649.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=2677

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4580.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.